Le Lézard
Classified in: Health, Covid-19 virus
Subjects: LGB, MRR

United States Sex Reassignment Surgery Market Analysis Report 2023: A $5 Billion Market by 2030 - Increasing Prevalence of Gender Dysphoria & Increasing Novel Hormonal Therapies with Better Efficacy


DUBLIN, Sept. 14, 2023 /PRNewswire/ -- The "U.S. Sex Reassignment Surgery Market Size, Share & Trends Analysis Report By Gender Transition (Female-to-male, Male-to-female), By Procedure (Mastectomy, Vaginoplasty, Scrotoplasty, Hysterectomy, Phalloplasty), And Segment Forecasts, 2023 - 2030" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo


The U.S. sex reassignment surgery market is projected to reach USD 5.0 billion by 2030, with a notable CAGR of 11.25% from 2023 to 2030.

This growth is attributed to several key factors. Firstly, the market is benefiting from an improved reimbursement landscape and government support, along with increasing awareness about transgender surgeries. The rising awareness is instrumental in promoting understanding and acceptance of transgender individuals and their healthcare needs. Gender-affirming hormone treatments, involving the use of estrogen or testosterone, play a significant role in aligning the physical characteristics of transgender individuals with their gender identity.

Furthermore, favorable government initiatives have contributed to the market's expansion. Notably, in June 2021, the U.S. Department of Veterans Affairs (VA) announced the inclusion of gender-affirming surgeries in its healthcare coverage for transgender veterans, which was a significant development. Previously, only hormone therapy and mental health services were covered. These government initiatives have played a pivotal role in driving market growth.

However, the COVID-19 pandemic had adverse effects on the U.S. sex reassignment surgery market. Plastic surgeons experienced a decline in the volume of services and procedures due to stringent pandemic regulations. Procedures like cosmetic and gender affirmation surgeries were particularly affected. Nevertheless, with the resumption of non-emergency services in clinics and hospitals across the U.S., the demand for sex reassignment surgeries is expected to rebound and contribute to market growth in the forecast period.

Among the various procedure segments, mastectomies held the largest market share in terms of revenue in 2022, driven by the growing recognition of transgender identity and rights. Additionally, augmentation mammoplasty is anticipated to exhibit the fastest CAGR over the forecast period, benefiting from increased affordability and availability of breast implants.

In terms of gender transition, the female-to-male gender transition segment dominated the market in 2022, with the largest revenue share of 59.81%. This trend is driven by the increasing number of transgender men opting for gender reassignment surgery due to positive outcomes and societal acceptance.

The U.S. sex reassignment market is characterized by fragmentation, with a few major players alongside several small- and medium-sized care centers. These companies have implemented various strategic initiatives to enhance their services in sex reassignment surgery, contributing to their significant market share. For instance, in April 2022, Cedars Sinai received recognition as an LGBTQ Health Care Equality Top Performer in the Human Rights Campaign Foundation's 2020 Health Care Equality Index.

Company Profiles

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope
3.1. Market Dynamics
3.1.1. Market Driver Analysis
3.1.1.1. Increasing prevalence of gender dysphoria
3.1.1.2. Improving reimbursement scenario and Government aids
3.1.1.3. Increasing public awareness about transgender surgeries
3.1.1.4. Increasing novel hormonal therapies with better efficacy
3.1.2. Market Restraint Analysis
3.1.2.1. High cost of procedures
3.1.2.2. Risks associated with surgical procedures
3.2. Industry Analysis Tools
3.2.1. Porter's Five Forces Analysis
3.2.2. PESTLE Analysis
3.3. Regulatory Framework & Reimbursement Scenario
3.4. Target Population Analysis
3.5. Patient Journey Analysis Based on a Hypothetical Case Study
3.6. COVID-19 Impact Analysis

Chapter 4. U.S. Sex Reassignment Surgery Market: Gender Transition Estimates & Trend Analysis
4.1. Segment Definitions
4.2. U.S. Sex Reassignment Surgery Market: Segment Dashboard
4.3. U.S. Sex Reassignment Surgery Market: Gender Transition Movement & Market Share Analysis
4.4. Male-to-Female
4.5. Female-to-Male

Chapter 5. U.S. Sex Reassignment Surgery Market: Procedure Estimates & Trend Analysis
5.1. Segment Definitions
5.2. U.S. Sex Reassignment Surgery Market: Segment Dashboard
5.3. U.S. Sex Reassignment Surgery Market: Region Movement & Market Share Analysis
5.4. Augmentation Mammoplasty
5.5. Voice Feminization Surgery
5.6. Reduction Thyrochondroplasty
5.7. Orchiectomy
5.8. Vaginoplasty
5.9. Chest Masculinization Surgery
5.10. Scrotoplasty
5.11. Hysterectomy
5.12. Phalloplasty
5.13. Mastectomy
5.14. Metoidioplasty
5.15. Facial Feminization Surgery

Chapter 6. Competitive Landscape
6.1. Overview
6.2. Financial Performance
6.3. Service Benchmarking
6.4. Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/85g9jy

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 09:05
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...

at 09:00
Today, the Honourable Gary Anandasangaree, Minister of Crown-Indigenous Relations; the Honourable Patty Hajdu, Minister of Indigenous Services and Minister responsible for FedNor; the Honourable Dan Vandal, Minister of Northern Affairs; and the...

at 08:05
GE HealthCare today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR...

at 07:00
To mark National Hospice Palliative Care Week, the Quebec Coalition for Palliative Care Access (the Coalition) is proud to celebrate the positive impact of palliative care on the well-being of people with life-limiting illness. Palliative care is...

at 06:00
A native born and trained Brazilian oncologist is in the forefront of a new era in the treatment of cancer patients with cutting edge proton therapy medical technology developed in Israel by P-Cure. "It is my dream to be able to bring the P-Cure...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...



News published on and distributed by: